Antibacterial Use and Resistance in Psychiatric Hospitals

Antibiotic stewardship in psychiatric hospitals presents a distinct clinical and epidemiological problem. Patients may have impaired self-care, frequent group contact, comorbid physical illness, or treatment-associated changes in immune status. Closed-care environments can also facilitate transmission, while respiratory viral outbreaks may increase concern about secondary bacterial infection. Against this background, the reference study examined whether antibacterial use in a psychiatric hospital during the 2022 epidemic was appropriately aligned with microbiological evidence and local resistance patterns.

Published in Scientific Reports, the article Analysis of antibacterial drug use and bacterial resistance in psychiatric hospital in the epidemic is important because it evaluates prescribing behavior and bacterial susceptibility within the same institutional setting. Rather than treating antibiotic consumption and resistance as separate quality indicators, the authors analyze them as related components of infection management.

Study Background and Research Question

The study was motivated by the difficulty of managing possible bacterial co-infection during a viral epidemic. Although bacterial infection is not present in every patient with a respiratory viral illness, the clinical uncertainty surrounding fever, inflammation, and respiratory symptoms can promote empiric antibiotic use. Psychiatric hospitals may be particularly vulnerable because patients often live in close proximity and may have limited ability to report symptoms or follow hygiene measures.

The authors therefore asked two linked questions: how were antibacterial drugs used in the psychiatric hospital during 2022, and what resistance patterns were observed among the bacterial isolates identified there? The research also compared selected antibiotic-use indicators with data from Jiangsu Province and national monitoring data. This comparison allowed the investigators to assess whether the hospital’s prescribing profile was unusually high, unusually low, or qualitatively different from broader practice.

The question is clinically relevant but should be interpreted narrowly. The study evaluates prescribing and resistance surveillance during a defined epidemic period; it does not test whether a particular antibiotic improves psychiatric or infectious-disease outcomes in a randomized comparison.

Key Innovation from the Reference Study

The central innovation is the integration of three evidence streams: hospital information-system records, national antibiotic-use monitoring, and laboratory susceptibility data. Many stewardship reports focus on drug consumption alone, while microbiology studies often describe resistance without examining the prescribing environment that may shape selection pressure. By combining these datasets, the investigators created a more operational view of antimicrobial management in a psychiatric institution.

A second strength is the emphasis on microbiological submission. The hospital’s reported submission rate for antibacterial drug use was higher than the corresponding Jiangsu and national levels, suggesting that prescribing decisions were more frequently accompanied by pathogen testing or specimen collection. This does not prove that every prescription was justified, but it provides a stronger basis for later de-escalation, escalation, or discontinuation than empiric treatment without microbiological information.

The study also identifies the actual drug classes dominating use. Third-generation cephalosporins, penicillins, and quinolones were the leading categories, with cefodizime, amoxicillin, and piperacillin–tazobactam among the most frequently used agents by cumulative defined daily doses. That detail is valuable because stewardship interventions should address the drugs that are actually being prescribed locally rather than relying on generic national priorities.

Methods and Experimental Design Insights

This was a retrospective observational analysis of antibacterial use and bacterial resistance in 2022. Utilization data for the hospital, Jiangsu Province, and China were retrieved from the National Antibacterial Drug Clinical Application Monitoring Network. The researchers also used the hospital information system to extract microbiological specimens, positive pathogen identifications, and drug-sensitivity results. Data were organized in Excel and analyzed according to antibiotic class and usage indicator.

The principal utilization variables included antibiotic use rate, antibiotic use intensity, combined medication rate, cumulative defined daily doses, and the percentage of antibiotic expenditure within total drug costs. The investigators additionally assessed the rate of microbiological submissions associated with antibacterial use and summarized resistance among Gram-negative and Gram-positive organisms. This design is suitable for describing institutional practice and identifying targets for quality improvement.

Protocol Parameters

• Observation period: The literature-backed analysis covered antibacterial use and microbiological data from 2022, the epidemic year specified by the authors; this is a study parameter rather than a universal surveillance interval.
• Data sources: Combine hospital information-system records with an established external antibiotic-monitoring network when benchmarking institutional use, as done in the reference study.
• Utilization metrics: Track use rate, antibiotic use intensity, combined therapy, cumulative defined daily doses, and antibiotic spending as separate indicators because no single metric captures prescribing quality.
• Microbiology linkage: Record whether antibacterial treatment was accompanied by specimen submission and connect positive cultures with susceptibility results whenever possible.
• Resistance reporting: Separate Gram-negative and Gram-positive organisms and report resistance by drug class or individual agent to reveal clinically actionable patterns.
• Follow-up assay design: For laboratory validation, define organism-specific controls, exposure ranges, and endpoints before testing; these are workflow recommendations and were not experimental parameters reported in the hospital study.

A major methodological insight is that utilization indicators should not be interpreted independently. A low overall use rate may coexist with concentrated exposure to a particular broad-spectrum class, while a high microbiological submission rate can improve decision quality without eliminating the need for review of initial prescribing. The retrospective design can reveal these relationships, but it cannot establish that one prescribing behavior caused a later resistance phenotype.

Core Findings and Why They Matter

The hospital reported an antibiotic use rate of 5.00%, antibiotic use intensity of 3.07, combined medication rate of 11.11%, cumulative DDDs of 12,039.04, and antibiotic costs representing 3.95% of total drug costs during 2022, according to the reference study. These values were lower than the reported Jiangsu and national levels. On the surface, this profile suggests relatively restrained antibacterial exposure and limited financial dependence on antibiotics.

However, the same hospital had a microbiological submission rate of 77.78%, higher than the provincial and national comparison levels. This is a meaningful finding because it shifts the interpretation from simple reduction of antibiotic volume toward evidence-supported prescribing. In a psychiatric setting, where symptom reporting and clinical assessment may be complicated, obtaining microbiological data can provide an important corrective to uncertainty-based empiric treatment.

Resistance remained substantial despite the relatively low overall use indicators. Gram-negative bacteria primarily showed resistance to penicillins, cephalosporins, and quinolones. The paper highlights resistance involving ampicillin, amoxicillin–clavulanic acid, ceftazidime, ceftriaxone, amikacin, and ciprofloxacin. Gram-positive bacteria mainly resisted penicillins, macrolides, and quinolones, with notable resistance to penicillin, benzylpenicillin, erythromycin, levofloxacin, and ciprofloxacin.

These results matter for two reasons. First, antibiotic quantity is an incomplete proxy for selection pressure: even lower aggregate use may be associated with clinically important resistance when prescribing is concentrated in vulnerable wards or repeated across the same patient population. Second, resistance patterns are local. A drug that appears appropriate from a national guideline perspective may be less reliable in a particular hospital if local isolates show elevated resistance.

The authors describe a complex relationship between antibacterial use and resistance, and they associate increased use in psychiatric settings with rising resistance and possible effects on treatment outcomes and prognosis. Because this conclusion comes from retrospective surveillance rather than causal modeling, the most defensible interpretation is that use and resistance should be monitored together. Regular review of culture results, susceptibility trends, and prescribing indications can help clinicians preserve effective options without assuming that lower total use alone guarantees rational therapy.

Comparison with Existing Internal Articles (if available)

The internal article Cefodizime (SKU BA1050): Reliable Antibiotic Solutions approaches the topic from a bench-science perspective, focusing on cell-viability and antimicrobial-assay workflows. It is complementary to the reference study because it addresses experimental reproducibility, whereas Jiang and colleagues address institutional prescribing and resistance surveillance. The two perspectives should not be conflated: an in vitro assay can define antibacterial responses under controlled conditions, but it cannot by itself establish appropriate hospital prescribing.

A second resource, Cefodizime: Third-Generation Cephalosporin Antibiotic, organizes mechanistic and pharmacological background around a bacterial cell wall synthesis inhibitor. This helps researchers frame laboratory questions about susceptibility and mechanism, while the reference paper supplies the clinical-surveillance context needed to interpret resistance risk. In practice, the literature supports using both levels of evidence carefully: mechanistic plausibility may justify an assay, but local susceptibility data remain essential for translational interpretation.

Limitations and Transferability

The study’s retrospective design limits causal inference. The observed relationship between antibiotic use and resistance may also reflect case mix, prior antimicrobial exposure, infection-control practices, colonization, specimen quality, or changes in laboratory testing. The condensed report does not provide enough information to determine how resistance rates changed over multiple years, how many isolates represented each organism, or whether repeated samples came from the same patients.

Generalizability is also limited. The analysis centers on one psychiatric hospital in Jiangsu Province during an unusual epidemic period. Its antibiotic-use profile may differ from that of general hospitals, long-term-care facilities, or psychiatric institutions in other regions. Comparisons with provincial and national indicators are useful for context, but they do not remove differences in patient characteristics, laboratory capacity, formulary structure, or reporting practices.

Another limitation is the absence of patient-level outcome analysis in the summarized findings. Antibiotic use rate and resistance are important stewardship endpoints, but they do not directly show clinical cure, adverse events, length of stay, mortality, or recurrence. Future work would benefit from linking prescriptions to indication, culture timing, treatment modification, and patient outcomes while preserving appropriate privacy protections.

Why this cross-domain matters, maturity, and limitations

Translating hospital surveillance into microbiology research is useful but remains a developing bridge. The reference study can identify which antibiotic classes and organisms deserve focused investigation; it cannot determine an assay’s optimal concentration, exposure schedule, or mechanistic endpoint. Conversely, laboratory experiments can clarify susceptibility or bacterial cell wall effects under controlled conditions, but they cannot reproduce the prescribing dynamics, patient vulnerability, and infection-control environment of a psychiatric hospital. The evidence is therefore mature for surveillance-guided question selection, but incomplete for direct prediction of clinical effectiveness.

Research Support Resources

For researchers designing related susceptibility, resistance, or infection-model workflows, Cefodizime (SKU BA1050) can support similar laboratory studies as a third-generation cephalosporin antibiotic and penicillin-binding protein inhibitor. The product information describes broad antibacterial activity, bacterial cell wall synthesis inhibition, and immunomodulatory properties; these features may be relevant when modeling antimicrobial activity against respiratory and urinary tract infections or evaluating an immunomodulatory antibiotic. Use the product specifications and organism-specific literature to define controls and exposure conditions, and treat the compound as a research reagent rather than as evidence of clinical efficacy or a kidney-safe antibiotic.